Spots Global Cancer Trial Database for recurrent adult acute myeloid leukemia

Every month we try and update this database with for recurrent adult acute myeloid leukemia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation	NCT00052520	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... B-cell Adult Ac... B-cell Childhoo... Childhood Chron... Childhood Myelo... Chronic Myelomo... Essential Throm... Polycythemia Ve... Previously Trea... Recurrent Adult... Recurrent Adult... Recurrent Child... Recurrent Child... Refractory Anem... Refractory Anem... Relapsing Chron... Secondary Acute... T-cell Adult Ac... T-cell Childhoo...	therapeutic all... aldesleukin peripheral bloo... allogeneic bone... laboratory biom... gene expression... immunologic tec... flow cytometry polymerase chai... cytogenetic ana... staining method	-	Fred Hutchinson Cancer Center
Romidepsin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	NCT00062075	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Pro... Recurrent Adult...	romidepsin	18 Years -	National Cancer Institute (NCI)
Radiolabeled Monoclonal Antibody, Cyclophosphamide, and Total Body Irradiation Followed By Donor Stem Cell Transplantation in Treating Patients With Advanced Acute Myeloid Leukemia	NCT00003868	Leukemia	cyclophosphamid... methotrexate allogeneic bone... peripheral bloo... iodine I 131 mo... radiation thera...	2 Years - 55 Years	Fred Hutchinson Cancer Center
Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant	NCT02333162	Previously Trea... Recurrent Adult... Recurrent Adult... Recurrent Hemat...	Fludarabine Pho... Melphalan Intensity-Modul... Total Marrow Ir... Allogeneic Hema... Peripheral Bloo... Allogeneic Bone... Tacrolimus Mycophenolate M... Laboratory Biom...	18 Years - 75 Years	University of Chicago
Decitabine Followed by Donor Lymphocyte Infusion for Patients With Relapsed Acute Myeloblastic Leukemia(AML) After Allogeneic Stem Cell Transplantation	NCT01758367	Recurrent Adult...	Deciatbine(DAC)	18 Years - 60 Years	Chinese PLA General Hospital
Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDS	NCT01300572	Chronic Myelomo... Previously Trea... Recurrent Adult... Recurrent Adult... Refractory Anem... Secondary Acute...	Allogeneic Bone... Allogeneic Hema... Cyclosporine Fludarabine Pho... Indium In 111 A... Laboratory Biom... Mycophenolate M... Peripheral Bloo... Pharmacological... Total-Body Irra... Yttrium Y 90 An...	18 Years -	Fred Hutchinson Cancer Center
Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Peripheral Stem Cell Transplantation	NCT00003056	Leukemia Lymphoma Graft Versus Ho...	cyclosporine cyclosporine an...	18 Years - 55 Years	Takeda
Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	NCT02299518	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Recurrent Adult... Secondary Acute...	mitoxantrone hy... etoposide cytarabine selinexor laboratory biom... pharmacological...	18 Years -	Ohio State University Comprehensive Cancer Center
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia or Acute Leukemia	NCT00004905	Leukemia	filgrastim recombinant int... cyclophosphamid... cytarabine etoposide idarubicin peripheral bloo... radiation thera...	18 Years - 60 Years	National Cancer Institute (NCI)
Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant	NCT01640301	Recurrent Adult... Recurrent Child... Secondary Acute... Therapy-Related... Donor Hematopoietic C... HLA-A*0201 Posi... Recurrent Acute...	Aldesleukin Cyclophosphamid... Fludarabine Pho... Laboratory Biom... WT1-Sensitized ...	-	Fred Hutchinson Cancer Center
Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome	NCT00445744	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Childhood Acute... Childhood Myelo... de Novo Myelody... Essential Throm... Myelodysplastic... Polycythemia Ve... Previously Trea... Primary Myelofi... Recurrent Adult... Recurrent Child... Secondary Acute... Secondary Myelo... Secondary Myelo... Untreated Adult... Untreated Child...	cyclophosphamid... busulfan tacrolimus methotrexate cytogenetic ana... flow cytometry pharmacological... pharmacogenomic... peripheral bloo... allogeneic hema...	- 65 Years	Fred Hutchinson Cancer Center
Relationship Between Natural Killer Cells' Ability to Kill Leukemia Cells and the Outcome of Patients With Acute Myeloid Leukemia Previously Treated With Interleukin-2	NCT00896701	Leukemia	flow cytometry immunologic tec... laboratory biom...	15 Years -	Alliance for Clinical Trials in Oncology
Bevacizumab, Cytarabine, and Mitoxantrone on Treating Patients With Hematologic Cancers	NCT00015951	Leukemia Myelodysplastic...	bevacizumab cytarabine mitoxantrone hy...	18 Years - 120 Years	University of Maryland, Baltimore
Clofarabine and Gemtuzumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	NCT00577694	Leukemia	clofarabine gemtuzumab ozog...	18 Years - 60 Years	UNC Lineberger Comprehensive Cancer Center
Mitomycin and Mitoxantrone in Treating Patients With Acute Myelogenous Leukemia	NCT00003003	Leukemia	sargramostim mitomycin C mitoxantrone hy...	18 Years - 120 Years	Dartmouth-Hitchcock Medical Center
Augmerosen Plus Fludarabine and Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia	NCT00004862	Leukemia	filgrastim oblimersen sodi... cytarabine fludarabine pho...	16 Years -	National Cancer Institute (NCI)
Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation or Isotretinoin in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphocytic Leukemia	NCT00003619	Chronic Myelopr... Leukemia Myelodysplastic... Thrombocytopeni...	filgrastim vitamin E busulfan cytarabine etoposide fludarabine pho... isotretinoin topotecan hydro... bone marrow abl... peripheral bloo...	19 Years - 90 Years	National Cancer Institute (NCI)
Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS	NCT02921061	Mixed Phenotype... Previously Trea... Recurrent Adult... Recurrent High ... Refractory Acut... Refractory High... Untreated Adult...	Cladribine Cytarabine Decitabine Filgrastim Laboratory Biom... Mitoxantrone Hy...	18 Years -	Fred Hutchinson Cancer Center
Study of Gemtuzumab Ozogamicin Therapy in DNA Samples From Patients With Acute Myeloid Leukemia Treated on COG-AAML0531	NCT01407757	Leukemia	DNA analysis gene expression... laboratory biom... pharmacogenomic...	- 29 Years	Children's Oncology Group
Gemtuzumab Ozogamicin and Cyclosporine in Treating Older Patients With Relapsed Acute Myeloid Leukemia	NCT00089050	Leukemia	cyclosporine gemtuzumab ozog...	60 Years -	Fred Hutchinson Cancer Center
Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia	NCT00818649	Leukemia Myelodysplastic...	bortezomib vorinostat	18 Years -	Masonic Cancer Center, University of Minnesota
Arsenic Trioxide in Treating Patients With Refractory or Recurrent Acute Promyelocytic Leukemia	NCT00008697	Leukemia	arsenic trioxid...	-	Washington University School of Medicine
Flavopiridol in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia	NCT00101231	Adult Acute Bas... Adult Acute Eos... Adult Acute Meg... Adult Acute Min... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Blastic Phase C... Recurrent Adult... Recurrent Adult... Relapsing Chron...	alvocidib	1 Year -	National Cancer Institute (NCI)
Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD	NCT00914940	Graft Versus Ho... Leukemia Myelodysplastic...	Fludarabine Pho... Tacrolimus Thiotepa Total-Body Irra... Magnetic Affini... Peripheral Bloo... Allogeneic Hema... T Cell-Depleted...	14 Years - 55 Years	Fred Hutchinson Cancer Center
Combination Chemotherapy Followed By Filgrastim or Sargramostim in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia	NCT00053131	Leukemia	filgrastim sargramostim cytarabine mitoxantrone hy...	15 Years -	Roswell Park Cancer Institute
Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome	NCT00475150	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... de Novo Myelody... Previously Trea... Recurrent Adult... Secondary Acute... Secondary Myelo... Untreated Adult...	cediranib malea... laboratory biom...	18 Years -	National Cancer Institute (NCI)
Combination Chemotherapy in Treating Patients With Recurrent or Refractory Leukemia	NCT00002588	Leukemia	etoposide topotecan hydro...	18 Years -	Case Comprehensive Cancer Center
Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia	NCT02381548	Acute Myeloid L... Blast Phase Chr... Myelodysplastic... Previously Trea... Recurrent Adult... Recurrent Chron... Refractory Acut... Refractory Chro... Secondary Acute... Therapy-Related... Untreated Adult...	Adavosertib Belinostat Laboratory Biom... Pharmacological...	18 Years -	National Cancer Institute (NCI)
Paclitaxel in Treating Patients With Refractory or Recurrent Acute Leukemia or Chronic Myelogenous Leukemia	NCT00003230	Leukemia	paclitaxel	18 Years - 75 Years	Swiss Group for Clinical Cancer Research
Cyclophosphamide Plus Topotecan in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia	NCT00003340	Leukemia	cyclophosphamid... topotecan hydro...	18 Years -	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid Leukemia	NCT01159301	Adult Acute Bas... Adult Acute Eos... Adult Acute Meg... Adult Acute Min... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Blastic Phase C... Recurrent Adult... Unspecified Adu...	entinostat sorafenib tosyl... pharmacological... laboratory biom...	18 Years -	National Cancer Institute (NCI)
VNP40101M and Cytarabine in Treating Patients With Hematologic Malignancies	NCT00070538	Leukemia Myelodysplastic...	cytarabine laromustine	18 Years -	National Cancer Institute (NCI)
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Acute Leukemia	NCT00008190	Leukemia	aldesleukin filgrastim busulfan cyclophosphamid... etoposide melphalan peripheral bloo...	-	National Cancer Institute (NCI)
Decitabine and Valproic Acid in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	NCT00079378	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Recurrent Adult... Recurrent Small... Refractory Chro... Untreated Adult...	decitabine valproic acid pharmacological... laboratory biom...	18 Years -	National Cancer Institute (NCI)
Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDS	NCT01300572	Chronic Myelomo... Previously Trea... Recurrent Adult... Recurrent Adult... Refractory Anem... Secondary Acute...	Allogeneic Bone... Allogeneic Hema... Cyclosporine Fludarabine Pho... Indium In 111 A... Laboratory Biom... Mycophenolate M... Peripheral Bloo... Pharmacological... Total-Body Irra... Yttrium Y 90 An...	18 Years -	Fred Hutchinson Cancer Center
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission	NCT00093470	Acute Myeloid L... Adult Acute Meg... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Alkylating Agen... Myelodysplastic... Recurrent Adult...	Clinical Observ... Tipifarnib	18 Years -	National Cancer Institute (NCI)
S9031-S9333-S0112-S0301-A Biomarkers Associated With Response to Cytarabine in Samples From Older Patients With Acute Myeloid Leukemia	NCT01338974	Leukemia	gene expression... proteomic profi... flow cytometry laboratory biom...	56 Years -	SWOG Cancer Research Network
Combination Chemotherapy in Treating Patients With Relapsed Acute Myelogenous Leukemia	NCT00003758	Leukemia	cytarabine idarubicin allogeneic bone... autologous bone... peripheral bloo...	15 Years - 60 Years	National Cancer Institute (NCI)
Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders	NCT00588991	Adult Acute Meg... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Chronic Myeloid... Chronic Myelomo... de Novo Myelody... Essential Throm... Hematopoietic a... Myelodysplastic... Polycythemia Ve... Recurrent Adult... Recurrent Adult... Secondary Myelo...	Carboplatin Laboratory Biom... Topotecan Hydro... Veliparib	18 Years -	National Cancer Institute (NCI)
Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer	NCT00027820	Adult Acute Mye... Childhood Acute... Childhood Acute... Childhood Myelo... Childhood Renal... Chronic Myelomo... Clear Cell Rena... de Novo Myelody... Metastatic Rena... Previously Trea... Progression of ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Refractory Anem... Refractory Anem... Refractory Chil... Refractory Chro... Renal Medullary... Type 1 Papillar... Type 2 Papillar... Untreated Adult... Untreated Adult... Untreated Child...	Fludarabine Pho... Total-Body Irra... Peripheral Bloo... Nonmyeloablativ... Cyclosporine Mycophenolate M...	-	Fred Hutchinson Cancer Center
BMS-214662 in Treating Patients With Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myeloid Leukemia	NCT00006213	Adult Acute Pro... Blastic Phase C... Childhood Myelo... Previously Trea... Recurrent Adult... Recurrent Adult... Recurrent Child... Recurrent Child... Refractory Anem... Refractory Anem... Relapsing Chron...	BMS-214662 pharmacological... laboratory biom...	15 Years -	National Cancer Institute (NCI)
6-Hydroxymethylacylfulvene in Treating Patients With Refractory Myelodysplastic Syndrome, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Blastic Phase Chronic Myelogenous Leukemia	NCT00003997	Leukemia Myelodysplastic...	irofulven	18 Years -	National Cancer Institute (NCI)
Study of MEN1112 Intravenous Infusion in Relapsed or Refractory Acute Myeloid Leukemia	NCT02353143	Recurrent Adult... Acute Myeloid L...	MEN1112	18 Years -	Menarini Group
Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia	NCT00217646	Adult Acute Bas... Adult Acute Eos... Adult Acute Meg... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Pro... Adult Erythrole... Adult Pure Eryt... Alkylating Agen... Blastic Phase de Novo Myelody... Previously Trea... Recurrent Adult... Recurrent Adult... Secondary Acute... Secondary Myelo...	Sorafenib Tosyl...	18 Years -	National Cancer Institute (NCI)
Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	NCT00634244	Adult Acute Meg... Adult Acute Min... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Recurrent Adult...	alvocidib mitoxantrone hy... carboplatin cytarabine sirolimus etoposide topotecan hydro...	18 Years - 65 Years	National Cancer Institute (NCI)
Monoclonal Antibody Therapy in Treating Patients With Chronic Lymphocytic Leukemia, Lymphocytic Lymphoma, Acute Lymphoblastic Leukemia, or Acute Myeloid Leukemia	NCT00017472	Extranodal Marg... Nodal Marginal ... Noncontiguous S... Noncontiguous S... Recurrent Adult... Recurrent Adult... Recurrent Margi... Recurrent Small... Refractory Chro... Splenic Margina... Stage III Margi... Stage III Small... Stage IV Margin... Stage IV Small ...	apolizumab laboratory biom... pharmacological...	18 Years -	National Cancer Institute (NCI)
Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia	NCT00392353	Acute Erythroid... Acute Megakaryo... Acute Myeloid L... Chronic Myelomo... Myelodysplastic... Myelodysplastic... Myelodysplastic... Recurrent Adult... Refractory Anem...	Azacitidine Laboratory Biom... Pharmacological... Vorinostat	18 Years -	National Cancer Institute (NCI)
Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	NCT01707004	Acute Myeloid L... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... de Novo Myelody... Previously Trea... Recurrent Adult... Secondary Acute...	decitabine fludarabine pho... busulfan cyclophosphamid... tacrolimus mycophenolate m... filgrastim total-body irra... allogeneic bone... laboratory biom...	18 Years - 75 Years	University of Wisconsin, Madison
Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant	NCT02333162	Previously Trea... Recurrent Adult... Recurrent Adult... Recurrent Hemat...	Fludarabine Pho... Melphalan Intensity-Modul... Total Marrow Ir... Allogeneic Hema... Peripheral Bloo... Allogeneic Bone... Tacrolimus Mycophenolate M... Laboratory Biom...	18 Years - 75 Years	University of Chicago
Chemotherapy, Total-Body Irradiation, Donor Natural Killer Cell Infusion, Aldesleukin, and UCB Transplant in Treating Patients With Relapsed or Refractory AML	NCT00871689	Leukemia	aldesleukin cyclophosphamid... fludarabine pho... umbilical cord ... total-body irra...	- 45 Years	Masonic Cancer Center, University of Minnesota
Chemotherapy in Treating Patients Who Have Hematologic Cancer	NCT00004047	Leukemia Myelodysplastic...	exatecan mesyla...	-	Daiichi Sankyo
Interleukin-2 in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia	NCT00003148	Leukemia	aldesleukin	18 Years - 60 Years	European Organisation for Research and Treatment of Cancer - EORTC
Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD	NCT00914940	Graft Versus Ho... Leukemia Myelodysplastic...	Fludarabine Pho... Tacrolimus Thiotepa Total-Body Irra... Magnetic Affini... Peripheral Bloo... Allogeneic Hema... T Cell-Depleted...	14 Years - 55 Years	Fred Hutchinson Cancer Center
Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After Stem Cell Transplant	NCT03537599	Minimal Residua... Recurrent Acute... Recurrent Adult... Recurrent Child...	Daratumumab Donor Lymphocyt... Laboratory Biom...	18 Years -	Ohio State University Comprehensive Cancer Center
Biomarkers in Bone Marrow and Blood Samples From Older Patients With Acute Myeloid Leukemia Treated With Cytarabine-Based Therapy	NCT01169363	Leukemia	proteomic profi... flow cytometry laboratory biom...	60 Years - 120 Years	Eastern Cooperative Oncology Group
Early Discharge and Outpatients Care in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Previously Treated With Intensive Chemotherapy	NCT01235572	Adult Acute Meg... Adult Acute Min... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Previously Trea... Recurrent Adult...	standard follow... medical chart r... quality-of-life...	18 Years - 75 Years	Fred Hutchinson Cancer Center
Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leukemia	NCT01839240	Adult Acute Meg... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Recurrent Adult... Secondary Acute... Untreated Adult...	azacitidine cytarabine mitoxantrone hy... laboratory biom...	18 Years -	University of Chicago
Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation	NCT00005641	Chronic Myelopr... Graft Versus Ho... Leukemia Multiple Myelom... Myelodysplastic...	anti-thymocyte ... busulfan cyclophosphamid... cyclosporine leucovorin calc... methotrexate methylprednisol... allogeneic bone... in vitro-treate... radiation thera...	15 Years - 60 Years	H. Lee Moffitt Cancer Center and Research Institute
Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myelogenous Leukemia or Refractory Anemia	NCT00278330	Blastic Phase C... Recurrent Adult... Recurrent Adult... Refractory Anem... Relapsing Chron... Untreated Adult... Untreated Adult...	alvocidib vorinostat	18 Years -	National Cancer Institute (NCI)
Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome	NCT00445744	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Childhood Acute... Childhood Myelo... de Novo Myelody... Essential Throm... Myelodysplastic... Polycythemia Ve... Previously Trea... Primary Myelofi... Recurrent Adult... Recurrent Child... Secondary Acute... Secondary Myelo... Secondary Myelo... Untreated Adult... Untreated Child...	cyclophosphamid... busulfan tacrolimus methotrexate cytogenetic ana... flow cytometry pharmacological... pharmacogenomic... peripheral bloo... allogeneic hema...	- 65 Years	Fred Hutchinson Cancer Center
Decitabine Followed by Donor Lymphocyte Infusion for Patients With Relapsed Acute Myeloblastic Leukemia(AML) After Allogeneic Stem Cell Transplantation	NCT01758367	Recurrent Adult...	Deciatbine(DAC)	18 Years - 60 Years	Chinese PLA General Hospital
Empirical Versus Preemptive Antifungal Therapy	NCT01288378	Fungal Infectio... Leukemia Myelodysplastic...	caspofungin ace...	18 Years -	European Organisation for Research and Treatment of Cancer - EORTC
Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia	NCT00087204	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Blastic Phase C... Chronic Myelomo... de Novo Myelody... Previously Trea... Recurrent Adult... Recurrent Adult... Refractory Anem... Refractory Anem... Relapsing Chron... Secondary Acute... Secondary Myelo...	becatecarin laboratory biom...	18 Years -	National Cancer Institute (NCI)
Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome	NCT00002989	Leukemia Lymphoma Multiple Myelom... Myelodysplastic...	busulfan cyclophosphamid... idarubicin melphalan radiation thera...	16 Years - 60 Years	National Cancer Institute (NCI)
Combination Chemotherapy in Treating Patients With Chronic Myelogenous Leukemia or Recurrent Acute Leukemia	NCT00002693	Leukemia Neutropenia	filgrastim carboplatin topotecan hydro...	18 Years -	Mayo Clinic
Imatinib Mesylate, Daunorubicin, and Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia	NCT00268229	Leukemia	cytarabine daunorubicin hy... imatinib mesyla...	18 Years -	The Cleveland Clinic
VNP40101M and Cytarabine in Treating Patients With Hematologic Malignancies	NCT00070538	Leukemia Myelodysplastic...	cytarabine laromustine	18 Years -	National Cancer Institute (NCI)
Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia	NCT01168219	Acute Myeloid L... Adult Acute Meg... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Alkylating Agen... de Novo Myelody... Myelodysplastic... Myelodysplastic... Recurrent Adult... Secondary Myelo...	Allogeneic Hema... Anti-Thymocyte ... Azacitidine Busulfan Fludarabine Pho... Laboratory Biom... Methotrexate Pharmacological... Tacrolimus	18 Years - 74 Years	National Cancer Institute (NCI)
Relationship Between Natural Killer Cells' Ability to Kill Leukemia Cells and the Outcome of Patients With Acute Myeloid Leukemia Previously Treated With Interleukin-2	NCT00896701	Leukemia	flow cytometry immunologic tec... laboratory biom...	15 Years -	Alliance for Clinical Trials in Oncology
DNA Analysis of Tumor Tissue From Patients With Acute Myeloid Leukemia	NCT00897936	Leukemia	DNA methylation... comparative gen... fluorescence in... microarray anal... polymerase chai... diagnostic labo... immunologic tec...	18 Years - 120 Years	Eastern Cooperative Oncology Group
Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children	NCT01858740	Accelerated Pha... Acute Biphenoty... Acute Leukemia ... Acute Undiffere... Adult Acute Lym... Adult Acute Mye... Blast Phase Chr... Childhood Acute... Childhood Acute... Chronic Myeloge... Myelodysplastic... Myelodysplastic... Recurrent Adult... Recurrent Adult... Recurrent Child... Recurrent Child... Refractory Adul... Refractory Chil...	Allogeneic Hema... Fludarabine Pho... Laboratory Biom... Methotrexate Peripheral Bloo... T Cell-Depleted... Tacrolimus Thiotepa Total-Body Irra...	- 21 Years	Fred Hutchinson Cancer Center
Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome	NCT00119366	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Childhood Myelo... Chronic Myelomo... Previously Trea... Recurrent Adult... Recurrent Child... Refractory Anem... Refractory Anem... Refractory Anem... Refractory Cyto... Secondary Acute... Secondary Myelo...	iodine I 131 mo... fludarabine pho... total-body irra... allogeneic hema... peripheral bloo... cyclosporine mycophenolate m... laboratory biom...	16 Years - 50 Years	Fred Hutchinson Cancer Center
Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML	NCT01849276	Adult Acute Meg... Adult Acute Min... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Blastic Phase C... Recurrent Adult... Untreated Adult...	metformin hydro... cytarabine laboratory biom...	18 Years -	Northwestern University
CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	NCT01768897	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Recurrent Adult...	CPI-613 cytarabine mitoxantrone hy... laboratory biom... pharmacological...	18 Years -	Wake Forest University Health Sciences
Gemcitabine and Mitoxantrone in Treating Patients With Relapsed Acute Myeloid Leukemia	NCT00268242	Leukemia	Gemcitabine Hyd... Mitoxantrone Hy...	18 Years -	The Cleveland Clinic
Chemotherapy and Total-Body Irradiation Followed by Donor Umbilical Cord Blood Transplant, Cyclosporine, and Mycophenolate Mofetil in Treating Patients With Hematologic Cancer	NCT00290641	Chronic Myelopr... Leukemia Lymphoma Myelodysplastic...	filgrastim graft-versus-tu... cyclophosphamid... cyclosporine fludarabine pho... mycophenolate m... umbilical cord ... radiation thera...	- 45 Years	Masonic Cancer Center, University of Minnesota
Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies	NCT01564277	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Blastic Phase C... Contiguous Stag... de Novo Myelody... Noncontiguous S... Previously Trea... Recurrent Adult... Recurrent Adult... Recurrent Adult... Stage I Adult B... Stage III Adult... Stage IV Adult ... Untreated Adult... Untreated Adult...	rasburicase allopurinol	18 Years -	Roswell Park Cancer Institute
VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma	NCT03017820	B-Cell Non-Hodg... Histiocytic and... Myelodysplastic... Previously Trea... Recurrent Adult... Recurrent Anapl... Recurrent Angio... Recurrent Mycos... Recurrent Plasm... Recurrent Prima... Recurrent T-Cel... Refractory Acut... Refractory Anap... Refractory Angi... Refractory Myco... Refractory Peri... Refractory Plas... Refractory Prim... Refractory T-Ce...	Biopsy Biospecimen Col... Bone Marrow Bio... Computed Tomogr... Cyclophosphamid... Positron Emissi... Recombinant Ves... Single Photon E... Cemiplimab	18 Years -	Mayo Clinic
Combination Chemotherapy, Donor Stem Cell Transplant, Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide in Treating Patients With Hematologic Cancer	NCT00782379	Leukemia Lymphoma Myelodysplastic...	busulfan cyclophosphamid... fludarabine pho... mycophenolate m... tacrolimus allogeneic hema... peripheral bloo...	18 Years - 60 Years	Northside Hospital, Inc.
Choline Magnesium Trisalicylate and Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia	NCT02144675	Adult Acute Meg... Adult Acute Min... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Recurrent Adult... Untreated Adult...	choline magnesi... idarubicin cytarabine laboratory biom...	18 Years -	Rutgers, The State University of New Jersey

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: